Only in Titles

Search results for: TCell

paperclip

#35015104   2022/01/11 To Up

[Development approaches for vaccines against hepatitis C virus infections].

The incidence of hepatitis C virus (HCV) infections remains high even more than 10 years after approval of the first direct-acting antivirals for treatment of hepatitis C. In some countries, more people are newly infected with the virus than patients cured by antiviral therapy. The development of a prophylactic vaccine could prevent virus transmission and thereby make a significant contribution to control the global burden of this disease. In this article, we review the unique challenges and current approaches to HCV vaccine development.HCV is a highly diverse and versatile virus that mostly escapes the immune system and establishes chronic infections. However, up to one third of the exposed individuals can spontaneously resolve HCV infections, which indicates that protective immunity can be achieved. Numerous studies on determinants of protective immunity against HCV show an increasingly complete picture of what a vaccine must achieve. It is very likely that both strong neutralizing antibodies and powerful cytotoxic T cells are needed to reliably protect against chronic HCV infection. The key question is which approaches allow maturation of particularly broadly effective antibodies and T cells. This will be necessary to protect against the high number of different HCV variants. The recent successes of mRNA vaccines open new doors for HCV vaccine research and development. Combined with a deeper understanding of the structure and function of the viral envelope proteins, the identification of cross-protective antibody and T‑cell epitopes as well as the use of standardized methods to quantify the effectiveness of vaccine candidates, new perspectives arise for the development of a vaccine.
Dorothea Bankwitz, Thomas Krey, Thomas Pietschmann

1731 related Products with: [Development approaches for vaccines against hepatitis C virus infections].

0.25 mg1,000 tests100μg50 ml2.5 mg100ug Lyophilized 1 G 6 ml Ready-to-use 100ug Lyophilized100ug1 mg

Related Pathways

paperclip

#35014680   2022/01/11 To Up

Role of TGM2 in T‑cell lymphoblastic lymphoma via regulation of IL‑6/JAK/STAT3 signalling.

Transglutaminase 2 (TGM2) is a Ca‑dependent enzyme that is closely associated with cancer progression; however, the function of TGM2 in T‑cell lymphoma remains unclear. In the present study, TGM2 was identified as an upregulated gene by bioinformatics analysis of the microarray datasets GSE132550 and GSE143382 from the Gene Expression Omnibus database. The effects and mechanisms of TGM2 on T‑cell lymphoma cells were evaluated using the Cell Counting Kit‑8, colony formation assay, 5‑ethynyl‑2'‑deoxyuridine (EdU) assay, flow cytometry, reverse transcription‑quantitative polymerase chain reaction, western blotting and gene set enrichment analysis (GSEA). TGM2 expression was shown to be elevated in formalin‑fixed paraffin‑embedded skin biopsies from patients with T‑cell lymphoma relative to skin tissue from healthy cases. TGM2 expression was also increased in T‑cell lymphoma cell lines compared with that in CD4 T cells. Transfection with TGM2 small interfering RNAs (siRNAs) decreased the number of EdU‑positive cells, and the viability and colony formation of T‑cell lymphoma cells. Furthermore, TGM2 siRNAs enhanced the apoptosis of T‑cell lymphoma cells potentially via cleavage of caspase‑3 and poly ADP‑ribose polymerase. GSEA identified the IL‑6/JAK/STAT3 pathway as a potential downstream signalling pathway of TGM2. Notably, the effects of TGM2 siRNAs on T‑cell lymphoma cells were attenuated by IL‑6 and accelerated by IL‑6/JAK/STAT3 inhibitor AG490. These findings indicated that TGM2 siRNAs inhibited the proliferation of T‑cell lymphoma cells by regulating the IL‑6/JAK/STAT3 signalling pathway; therefore, TGM2 may function as a potential therapeutic target for T‑cell lymphoma.
Yuyan Wang, Ni Zheng, Tingting Sun, Hui Zhao, Ying Chen, Congcong Liu

1017 related Products with: Role of TGM2 in T‑cell lymphoblastic lymphoma via regulation of IL‑6/JAK/STAT3 signalling.

2 Pieces/Box5 mg50 ug96 wells1 mg5 x 50 ug96 samples5 x 10A5 cells/vial100ug Lyophilized

Related Pathways

paperclip

#34998198   2021/12/30 To Up

Acute disseminated candidiasis due to Candida tropicalis with skin and muscular lesions in a patient with Tcell acute lymphocytic leukemia (T-ALL).

Candida tropicalis is the Candida species that is mostly involved in case of acute disseminated candidiasis. We report here a case with whole body dissemination (pulmonary, cutaneous, muscular, hepatic, spinal and cerebral) highlighted by impressive imagery obtained by positron emission tomography scanner in a patient treated for T cell acute lymphocytic leukemia.
Bellanger Ap, Labaigt T, Brunel As, Scherer E, Grenouillet F, Berceanu A

1040 related Products with: Acute disseminated candidiasis due to Candida tropicalis with skin and muscular lesions in a patient with Tcell acute lymphocytic leukemia (T-ALL).

100

Related Pathways

paperclip

#34988613   2022/01/05 To Up

[Current therapeutic options in Mycosis fungoides and Sézary syndrome].

Driven by the approval of new targeted therapies, significant progress has been made in recent years in the clinical management of cutaneous T‑cell lymphomas. Although there are no curative treatment options for cutaneous T‑cell lymphomas, response rates are often encouraging, in particular when using combination therapies. The decision for the appropriate form of treatment depends on the specific diagnosis, disease stage, and the history of prior therapies. This article provides a comprehensive overview of current treatment options in mycosis fungoides and Sézary syndrome, based on the recently published, revised German S2k guidelines on cutaneous lymphomas (update 2021). In addition, we present promising, yet-to-be-approved therapies that at least in part can be already used off-label in clinical practice today.
Jana Dorothea Albrecht, Jan Peter Nicolay

1608 related Products with: [Current therapeutic options in Mycosis fungoides and Sézary syndrome].

100 μg100 μg1100 μg

Related Pathways

paperclip

#34980602   2022/01/03 To Up

Circulating CD137 T Cells Correlate with Improved Response to Anti-PD1 Immunotherapy in Patients with Cancer.

CD137 molecule is expressed by activated lymphocytes, and in patients with cancer identifies the tumor-reactive T cells. In solid tumors, high levels of circulating CD137 T cells are associated with the clinical response and the disease-free status. Here, we examined the role of the CD137 T cells in the improvement of patients' selection for immunotherapy treatment.
Ilaria Grazia Zizzari, Alessandra Di Filippo, Andrea Botticelli, Lidia Strigari, Angelina Pernazza, Emma Rullo, Maria Gemma Pignataro, Alessio Ugolini, Fabio Scirocchi, Francesca Romana Di Pietro, Ernesto Rossi, Alain Gelibter, Giovanni Schinzari, Giulia D'Amati, Aurelia Rughetti, Paolo Marchetti, Marianna Nuti, Chiara Napoletano

1412 related Products with: Circulating CD137 T Cells Correlate with Improved Response to Anti-PD1 Immunotherapy in Patients with Cancer.



Related Pathways

paperclip

#34967910   2021/12/30 To Up

[Clinical update-multiple myeloma].

Multiple myeloma (MM) is a malignancy of hematopoetic system and is associated with destruction of bone, suppressed bone marrow function and renal failure. It is characterized by strong proliferation of malignant plasma cells.
Hartmut Goldschmidt

2547 related Products with: [Clinical update-multiple myeloma].



Related Pathways

paperclip

#34913075   2021/12/16 To Up

Niclosamide suppresses T‑cell acute lymphoblastic leukemia growth through activation of apoptosis and autophagy.

T‑cell acute lymphoblastic leukemia (T‑ALL) is a common pediatric malignancy, characterized by the abnormal presence of immature T‑cell progenitors. Conventional treatments for T‑ALL fail to prevent or cure the disease, with a high‑risk of recurrence after the first remission. Thus, medical options are in demand to develop novel therapies for patients suffering with T‑ALL. Niclosamide, a traditional oral anti‑helminthic drug, has been reported to be a potential anticancer agent that regulates intracellular signaling pathways. Few studies have yet investigated the effects of niclosamide on the development of T‑ALL. Here, the present study aimed to investigate the anti‑leukemia effects of niclosamide on T‑ALL. We first hypothesized that the suppressive effects of niclosamide on the tumor growth of T‑ALL are exerted by regulating autophagy and apoptosis. Following niclosamide treatment, T‑ALL cell viability was evaluated using MTT assay, and apoptosis with Annexin V/propidium iodide staining. In T‑ALL cells treated with niclosamide, changes in apoptosis‑ and autophagy‑related proteins were analyzed by western blotting. In addition, in an model, T‑ALL xenograft mice were used to study the anti‑leukemia effects of niclosamide. The results showed that niclosamide significantly reduced the viability of Jurkat and CCRF‑CEM T‑ALL cells in both a dose‑ and time‑dependent manner. Niclosamide significantly activated the early and late phases of apoptosis in Jurkat (at 2 µM) and CCRF‑CEM cells (at 1 µM). Furthermore, niclosamide upregulated protein expression of cleaved caspase‑3 and LC3B, while downregulated those of Bcl‑2 and p62, in a dose‑dependent manner in both Jurkat and CCRF‑CEM cells. The results showed that niclosamide treatment significantly suppressed tumor growth and the disease progression in T‑ALL xenograft mice by activating cleaved caspase‑3 and LC3B. We conclude that niclosamide plays an anti‑leukemia role, and that it represents a novel approach for the treatment of T‑ALL.
Fang-Liang Huang, Sheng-Jie Yu, En-Chih Liao, Long-Yuan Li, Pei-Wen Shen, Chia-Ling Li

2644 related Products with: Niclosamide suppresses T‑cell acute lymphoblastic leukemia growth through activation of apoptosis and autophagy.

1 kit1 kit1 kit50 ug15 1 kit1 kit1 kit1 kit200 Tests

Related Pathways

paperclip

#34759327   2021/11/10 To Up

Author Correction: DES-Tcell is a knowledgebase for exploring immunology-related literature.


Ahdab AlSaieedi, Adil Salhi, Faroug Tifratene, Arwa Bin Raies, Arnaud Hungler, Mahmut Uludag, Christophe Van Neste, Vladimir B Bajic, Takashi Gojobori, Magbubah Essack

2031 related Products with: Author Correction: DES-Tcell is a knowledgebase for exploring immunology-related literature.

0.25 mg100 ml1 ml0.1 ml 100ul25 µg1 g0.1 mg100 TESTS0.2 mg0.1ml (1mg/ml)0.1 mg

Related Pathways

    No related Items
paperclip

#34749670   2021/11/08 To Up

Case report of Ureaplasma urealyticum meningitis in a patient with thymoma and hypogammaglobulinaemia.

Ureaplasma urealyticum (UU) is found among the normal vaginal flora in a considerable proportion of asymptomatic women; however, adult central nervous system (CNS) infection of UU is extremely rare. Good's syndrome (GS) is an adult-onset immunodeficiency characterized by thymoma, hypogammaglobulinaemia, low or absent B‑cells, and an inverted CD4+/CD8+ T‑cell ratio. Patients with GS usually have severe or recurrent infections.
Ting Zhang, Haiyan Li, Shuping Hou, Huanxin Yu, Wei Yue

1661 related Products with: Case report of Ureaplasma urealyticum meningitis in a patient with thymoma and hypogammaglobulinaemia.



Related Pathways

paperclip

#34691055   2021/10/07 To Up

Sarcoidosis Following Hematopoietic Stem Cell Transplantation: Clinical Characteristics and HLA Associations.

Extrinsic factors and genetic predisposition contribute to the etiology of sarcoidosis, converging in a phenotype of altered immune response associated with multisystemic inflammatory granulomatous tissue infiltration. Immunological reconstitution after hematopoietic stem cell transplantation (HSCT) may represent a unique window for the pathogenesis of the disease. We describe the incidence, clinicopathological features, and HLA associations of sarcoidosis after HSCT in a single-center cohort of patients, together with data from previously published cases.
Rebecca Isabel Wurm-Kuczera, Judith Buentzel, Julia Felicitas Leni Koenig, Tobias Legler, Jan-Jakob Valk, Justin Hasenkamp, Wolfram Jung, Jan-Gerd Rademacher, Peter Korsten, Gerald Georg Wulf

2797 related Products with: Sarcoidosis Following Hematopoietic Stem Cell Transplantation: Clinical Characteristics and HLA Associations.

5 ug1 mg3 Modulators10 ug24 wells100 µg3 Modulators1 x 10^6 cells/vial

Related Pathways